Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
A phase 1/2 trial of Erdafitinib in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer is a phase 1/2 interventional study registered as NCT05316155 by Janssen Research & Development, LLC, with 235 participants enrolled, started 2022-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: Erdafitinib Intravesical Delivery System.
Similar pages
not linked directly; found by shared links- TrialAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Johnson & Johnson and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag pipeline.